Arterial Blood Gas Kits Market Forecast to 2028: Research & Markets

 

“Arterial Blood Gas Kits Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product Type (1mL (Syringe Volume), 3mL (Syringe Volume), and Others); End User (Hospitals, Clinics, and Others), and Geography” report has been added to ResearchAndMarkets.com’s offering.

Growing Geriatric Population Likely to Gain Traction in Arterial Blood Gas Kits Market During 2020-2028

Arterial Blood Gas Kits Market is expected to reach US$ 773.01 million in 2028 from US$ 455.84 million in 2021 growing at a CAGR of 7.8% from 2021-2028.

The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.

Becton Dickinson and Company, Radiometer Medical ApS, Smiths Medical, Vyaire Medical, Opti Medical Systems, Inc., Westmed Medical, Siemens Healthineers AG, ITL Biomedical, i-SENS, Inc., and Teleflex Incorporated amongst others are the leading companies operating in the micro catheters and micro guidewires market.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Arterial Blood Gas Kits market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Arterial Blood Gas Kits market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction

2. Arterial Blood Gas Kits Market – Key Takeaways

3. Research Methodology

4. Global Arterial Blood Gas Kits Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinions

5. Arterial Blood Gas Kits Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Respiratory Diseases

5.1.2 Growing Prevalence of Metabolic and Kidney Diseases

5.2 Market Restraints

5.2.1 Risks, Complications, and Sampling Errors Associated with Arterial Blood Sampling

5.3 Market Opportunities

5.3.1 Growing Geriatric Population

5.4 Future Trends

5.4.1 Strategic Developments by Manufacturers

5.5 Impact Analysis

6. Arterial Blood Gas Kits Market – Global Analysis

6.1 Global Arterial Blood Gas Kits Market Revenue Forecast and Analysis

6.2 Global Arterial Blood Gas Kits Market, By Geography – Forecast and Analysis

6.3 Market Positioning of Key Players

7. Arterial Blood Gas Kits Market Analysis By Product

7.1 Overview

7.2 Arterial Blood Gas Kits Market Revenue Share, by Product (2021 and 2028)

7.3 1ml (Syringe Volume)

7.4 3ml (Syringe Volume)

8. Arterial Blood Gas Kits Market – By End User

8.1 Overview

8.2 Arterial Blood Gas Kits Market Revenue Share, by End User (2021 and 2028)

8.3 Hospitals

8.4 Clinics

9. Arterial Blood Gas Kits Market – Geographic Analysis

9.1 Arterial Blood Gas Kits Market – Revenue and Forecast to 2028 (USD Million)

9.2 Arterial Blood Gas Kits Market, by Product – Revenue and Forecast to 2028 (USD Million)

9.3.Arterial Blood Gas Kits Market, by End User – Revenue and Forecast to 2028 (USD Million)

9.4 Arterial Blood Gas Kits Market, by Country, 2021& 2028 (%)

10. Impact of COVID-19 Pandemic on Global Arterial Blood Gas Kits Market

11. Arterial Blood Gas Kits Market-Industry Landscape

11.1 Overview

11.2 Growth Strategies Done by the Companies in the Market, (%)

11.3 Organic Developments

11.4 Inorganic Developments

12. Company Profiles

  • Becton Dickinson and Company
  • Radiometer Company
  • Smiths Medical
  • Vyaire Medical
  • OPTI Medical
  • Westmed Medical
  • CareFusion(Cardinal Health)
  • Fisher Scientific
  • ITL BioMedical
  • Typenex Medical, LLC

For more information about this report visit https://www.researchandmarkets.com/r/v4t7ec

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”